Everycell's Effect on DNA Damage, Inflammation, and Stress

Family Member Clinical Trial

Official title:

The Effect of Dietary Supplementation on DNA Damage, Inflammation, Stress, and Related Factors Important in Somatic and Stem Cell Senescence in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02032693
• Other study ID #: 20130411
• Status: Completed
• Phase: N/A
• First received: January 2, 2014
• Last updated: May 22, 2014
• Start date: December 2013
• Est. completion date: April 2014

Study information

• Verified date: May 2014
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The investigators are conducting this research because they want to determine if a dietary supplement, called Everycell™, has an effect on the functioning of the study participants' cells. The results of this research will be used to help develop additional strategies for trying to fight the effects of aging. The primary purpose of this study is to determine the effectiveness of Everycell™ compared to placebo (a pill that does nothing) on DNA damage, inflammation, stress, and related factors. Taking Everycell™ is not a medical prescription, treatment, or cure for any known disease or condition.

Helping patients' nutritional status is important to prevent the continued worsening of chronic diseases and also to counteract the effects of aging. Americans also have difficulties with compliance to prescription medications due to their toxicity and side effects. This study aims to learn more about how a dietary supplement may improve nutritional status and enable the body to normalize cellular functioning, which may improve quality of life. The results of this research will be used to determine if Everycell™ is beneficial for overall cellular health and to counteract the effects of aging.

Description:

The proposed study is a 6-week, randomized, double-blind, placebo-controlled trial to evaluate the effect of everycell compared to placebo on DNA damage, inflammation, stress, and related factors in 30 healthy adults (18-55 years of age). Participants will be assessed at baseline, 4 weeks (end of intervention), and 6 weeks (2-week washout period), and the study will consist of two treatment arms, including: (a) Everycell and (b) placebo. Additionally, the study will examine subject health-related quality of life (QoL).

Specific Aim. Test the effect of Everycell compared to placebo on DNA damage, inflammation, stress, and related factors in a sample of healthy adults.

Hypothesis. The Everycell group will demonstrate improvements in DNA damage, inflammation, stress, and related factors at 4 and 6-week follow-ups compared to placebo.

Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.

No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. The components of everycell should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by CellHealth Institute, the manufacturer of the product, many customers currently use Everycell, and CellHealth Institute is unaware of significant toxicities.

CellHealth Institute applies the latest scientific methods to ensure the value and safety of their raw materials. CellHealth Institute products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.

Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.

Alternatives to this study for improving DNA damage, inflammation, and stress include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for DNA damage, inflammation, and stress, but their long-term use has unknown consequences.

The information obtained in this study will help in determining the efficacy of using a nutritional supplement for improving DNA damage, inflammation, and stress outcomes. By participating in the study, subjects may experience improved DNA damage, inflammation, and stress. The risk of participating in this study is reasonable because of the potential enhancements in DNA damage, inflammation, and stress with improved nutritional status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Be between the ages of 18 and 55

• Live independently without medical assistance

• Willing to provide informed consent to participate in the study

• Willing to follow our procedures and requirements for the study, including:

1. providing blood, urine, and saliva samples

2. completing other assessments

• Patients may take a similar dietary supplement as the one used in the study, but they must stop taking all similar dietary supplements 2 weeks prior to starting the study and for the 6 weeks duration of the study.

Exclusion Criteria:

• Patients need to be free of major medical conditions, such as neurological, cardiovascular, pulmonary, renal, endocrine, thyroid, hepatic, autoimmune, or bone/joint disorders or conditions; psychiatric diagnoses or psychotic disorders, and have no gastrointestinal disorders that could affect how the dietary supplement is absorbed by their body.

• Cannot participate in another similar research trial within 30 days of participating in this study

• Cannot be a smoker or have stopped smoking less than 6 months ago

• Cannot currently be taking any chemotherapy or radiation treatment for cancer

• Cannot be diagnosed with a terminal illness

• Cannot be diagnosed with insulin-dependent diabetes and/or be taking metformin

• Cannot be HIV positive

• If female, the patient cannot currently be pregnant, breastfeeding, or intending to become pregnant within the next month

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Family Member
• Inflammation

Intervention

Dietary Supplement:
• Everycell™

Other:
• Placebo

Locations

Country	Name	City	State
United States	University of Miami Miller School of Medicine, Clinical Research Building	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	CellHealth Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Fructosamine at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Protein Thiol Test at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Homocysteine at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Telomere Length at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 8 at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in 8-hydroxydeoxyguanosine at 4 weeks	Urine sample for 8-OHdG and 8-epi-PGF-2-alpha	Baseline, 4-week follow-up	No
Primary	Change from Baseline in 8-epi-PGF-2-alpha at 4 weeks	Urine sample for 8-OHdG and 8-epi-PGF-2-alpha	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 4 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 4-week follow-up	No
Primary	Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Fructosamine at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Protein Thiol Test at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Homocysteine at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Telomere Length at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 8 at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in 8-hydroxydeoxyguanosine at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in 8-epi-PGF-2-alpha at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Primary	Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 6 weeks	Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Systolic Blood Pressure at 4 weeks	Systolic and diastolic blood pressure measured.	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Pulse at 4 weeks		Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Waist Circumference at 4 weeks	Measure of body composition: waist circumference (cm).	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Hip Circumference at 4 weeks	Measure of body composition: hip circumference (cm).	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Weight at 4 weeks	Measure of body composition: weight.	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Height at 4 weeks	Measure of body composition: height.	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Body Mass Index at 4 weeks	Measure of body composition: height and weight to assess BMI.	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in International Physical Activity Questionnaire at 4 weeks		Baseline, 4-week follow-up	No
Secondary	Change from Baseline in SF-36v2™ Health Survey at 4 weeks		Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Systolic Blood Pressure at 6 weeks	Systolic and diastolic blood pressure measured.	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Diastolic Blood Pressure at 4 weeks	Systolic and diastolic blood pressure measured.	Baseline, 4-week follow-up	No
Secondary	Change from Baseline in Diastolic Blood Pressure at 6 weeks	Systolic and diastolic blood pressure measured.	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Pulse at 6 weeks		Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Waist Circumference at 6 weeks	Measure of body composition: waist circumference (cm).	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Hip Circumference at 6 weeks	Measure of body composition: hip circumference (cm).	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Weight at 6 weeks	Measure of body composition: weight.	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Height at 6 weeks	Measure of body composition: height.	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in Body Mass Index at 6 weeks	Measure of body composition: height and weight to assess BMI.	Baseline, 6-week follow-up	No
Secondary	Change from Baseline in International Physical Activity Questionnaire at 6 weeks		Baseline, 6-week follow-up	No
Secondary	Change from Baseline in SF-36v2™ Health Survey at 6 weeks		Baseline, 6-week follow-up	No